Do analysts prefer BCLI or FLGC?

Flora Growth has a consensus price target of $30.00, suggesting a potential upside of 1,239.29%. Given Flora Growth's higher probable upside, analysts clearly believe Flora Growth is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to KTTA or FLGC?

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Flora Growth. Pasithea Therapeutics' average media sentiment score of 0.63 beat Flora Growth's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Flora Growth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BLRX or FLGC?

Flora Growth has a consensus price target of $30.00, indicating a potential upside of 1,239.29%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BLRX or FLGC more profitable?

Flora Growth has a net margin of -32.03% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Flora Growth's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% Flora Growth -32.03% -64.02% -34.46%

Does the media prefer BLRX or FLGC?

In the previous week, BioLineRx had 3 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for BioLineRx and 1 mentions for Flora Growth. BioLineRx's average media sentiment score of 0.47 beat Flora Growth's score of 0.00 indicating that BioLineRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Flora Growth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BFRG or FLGC?

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 1,239.29%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BFRG or FLGC more profitable?

Bullfrog AI has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bullfrog AI N/A -217.80% -174.57% Flora Growth -32.03% -64.02% -34.46%

Flora Growth (FLGC) Competitors

$2.24 -0.25 (-10.04%)

As of 07/10/2026

Compare

FLGC vs. BCLI, KTTA, BLRX, LEXX, and BFRG

Should you buy Flora Growth stock or one of its competitors? MarketBeat compares Flora Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Flora Growth include Brainstorm Cell Therapeutics (BCLI), Pasithea Therapeutics (KTTA), BioLineRx (BLRX), Lexaria Bioscience (LEXX), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry.

How does Flora Growth compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Flora Growth had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 1 mentions for Flora Growth and 0 mentions for Brainstorm Cell Therapeutics. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Flora Growth	Neutral

Flora Growth has a consensus price target of $30.00, suggesting a potential upside of 1,239.29%. Given Flora Growth's higher probable upside, analysts clearly believe Flora Growth is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Brainstorm Cell Therapeutics has higher earnings, but lower revenue than Flora Growth. Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Flora Growth	$57.61M	0.04	-$15.91M	-$32.49	N/A

Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Flora Growth	-32.03%	-64.02%	-34.46%

Summary

Flora Growth beats Brainstorm Cell Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Flora Growth compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 2.0% of Pasithea Therapeutics shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Flora Growth has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A
Flora Growth	$57.61M	0.04	-$15.91M	-$32.49	N/A

In the previous week, Pasithea Therapeutics had 2 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 1 mentions for Flora Growth. Pasithea Therapeutics' average media sentiment score of 0.63 beat Flora Growth's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Flora Growth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

Pasithea Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Pasithea Therapeutics' return on equity of -57.44% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-57.44%	-53.61%
Flora Growth	-32.03%	-64.02%	-34.46%

Pasithea Therapeutics currently has a consensus target price of $3.00, suggesting a potential upside of 512.24%. Flora Growth has a consensus target price of $30.00, suggesting a potential upside of 1,239.29%. Given Flora Growth's higher probable upside, analysts clearly believe Flora Growth is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Flora Growth beats Pasithea Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Flora Growth compare to BioLineRx?

BioLineRx (NASDAQ:BLRX) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 36.0% of Flora Growth shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 2.3% of Flora Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Flora Growth has a net margin of -32.03% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Flora Growth	-32.03%	-64.02%	-34.46%

BioLineRx has higher earnings, but lower revenue than Flora Growth. BioLineRx is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	11.48	-$1.17M	-$1.92	N/A
Flora Growth	$57.61M	0.04	-$15.91M	-$32.49	N/A

In the previous week, BioLineRx had 3 more articles in the media than Flora Growth. MarketBeat recorded 4 mentions for BioLineRx and 1 mentions for Flora Growth. BioLineRx's average media sentiment score of 0.47 beat Flora Growth's score of 0.00 indicating that BioLineRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Flora Growth	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLineRx has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Flora Growth has a consensus price target of $30.00, indicating a potential upside of 1,239.29%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts plainly believe Flora Growth is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Flora Growth beats BioLineRx on 9 of the 16 factors compared between the two stocks.

How does Flora Growth compare to Lexaria Bioscience?

Flora Growth (NASDAQ:FLGC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

Lexaria Bioscience has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Lexaria Bioscience	N/A	-206.02%	-162.53%

Flora Growth currently has a consensus price target of $30.00, indicating a potential upside of 1,239.29%. Lexaria Bioscience has a consensus price target of $1.50, indicating a potential upside of 152.14%. Given Flora Growth's higher probable upside, equities analysts plainly believe Flora Growth is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Lexaria Bioscience had 1 more articles in the media than Flora Growth. MarketBeat recorded 2 mentions for Lexaria Bioscience and 1 mentions for Flora Growth. Lexaria Bioscience's average media sentiment score of 0.62 beat Flora Growth's score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Flora Growth	Neutral
Lexaria Bioscience	Positive

Flora Growth has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lexaria Bioscience has lower revenue, but higher earnings than Flora Growth. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.04	-$15.91M	-$32.49	N/A
Lexaria Bioscience	$710K	20.77	-$11.90M	-$0.47	N/A

Summary

Flora Growth and Lexaria Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Bullfrog AI?

Bullfrog AI (NASDAQ:BFRG) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 1,239.29%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts plainly believe Flora Growth is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Bullfrog AI had 1 more articles in the media than Flora Growth. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for Flora Growth. Bullfrog AI's average media sentiment score of 1.43 beat Flora Growth's score of 0.00 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Flora Growth	Neutral

Bullfrog AI has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Flora Growth	-32.03%	-64.02%	-34.46%

Bullfrog AI has higher earnings, but lower revenue than Flora Growth. Bullfrog AI is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120K	105.21	-$6.50M	-$0.54	N/A
Flora Growth	$57.61M	0.04	-$15.91M	-$32.49	N/A

Bullfrog AI has a beta of -2.8, meaning that its stock price is 380% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Summary

Flora Growth beats Bullfrog AI on 9 of the 16 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGC vs. The Competition

Export

Metric	Flora Growth	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.34M	$8.82B	$7.05B	$12.61B
Dividend Yield	N/A	2.54%	2.68%	8.00%
P/E Ratio	-0.07	16.09	27.11	24.26
Price / Sales	0.04	7.04	589.96	117.88
Price / Cash	N/A	18.40	29.22	49.36
Price / Book	0.18	3.57	10.74	6.29
Net Income	-$15.91M	$228.19M	$3.58B	$330.66M
7 Day Performance	-28.89%	-2.31%	-2.11%	-1.35%
1 Month Performance	-50.88%	-0.62%	3.27%	-0.64%
1 Year Performance	-91.66%	-2.73%	26.31%	19.08%

Flora Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGC Flora Growth	1.4301 of 5 stars	$2.24 -10.0%	$30.00 +1,239.3%	-91.6%	$2.34M	$57.61M	N/A	280	News Coverage Gap Down
BCLI Brainstorm Cell Therapeutics	0.1775 of 5 stars	$1.21 -1.9%	N/A	-12.9%	$13.35M	N/A	N/A	40	Gap Down
KTTA Pasithea Therapeutics	3.3177 of 5 stars	$0.52 +0.2%	$3.00 +475.8%	-28.9%	$13.07M	N/A	N/A	3
BLRX BioLineRx	0.6872 of 5 stars	$2.95 -6.6%	N/A	-34.0%	$12.88M	$1.18M	N/A	40	Gap Up High Trading Volume
LEXX Lexaria Bioscience	2.1465 of 5 stars	$0.52 -2.9%	$1.50 +191.3%	-32.5%	$12.77M	$710K	N/A	7	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGC) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Flora Growth (FLGC) Competitors

FLGC vs. BCLI, KTTA, BLRX, LEXX, and BFRG

How does Flora Growth compare to Brainstorm Cell Therapeutics?

Summary

How does Flora Growth compare to Pasithea Therapeutics?

Summary

How does Flora Growth compare to BioLineRx?

Summary

How does Flora Growth compare to Lexaria Bioscience?

Summary

How does Flora Growth compare to Bullfrog AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Flora Growth (FLGC) Competitors

FLGC vs. BCLI, KTTA, BLRX, LEXX, and BFRG

How does Flora Growth compare to Brainstorm Cell Therapeutics?

Does the media refer more to BCLI or FLGC?

Do analysts prefer BCLI or FLGC?

Which has better valuation & earnings, BCLI or FLGC?

Which has more volatility and risk, BCLI or FLGC?

Do institutionals and insiders hold more shares of BCLI or FLGC?

Is BCLI or FLGC more profitable?

Summary

How does Flora Growth compare to Pasithea Therapeutics?

Do institutionals & insiders hold more shares of KTTA or FLGC?

Which has higher earnings and valuation, KTTA or FLGC?

Does the media refer more to KTTA or FLGC?

Which has more risk & volatility, KTTA or FLGC?

Is KTTA or FLGC more profitable?

Do analysts prefer KTTA or FLGC?

Summary

How does Flora Growth compare to BioLineRx?

Do institutionals and insiders believe in BLRX or FLGC?

Is BLRX or FLGC more profitable?

Which has preferable earnings and valuation, BLRX or FLGC?

Does the media prefer BLRX or FLGC?

Which has more risk and volatility, BLRX or FLGC?

Do analysts prefer BLRX or FLGC?

Summary

How does Flora Growth compare to Lexaria Bioscience?

Is FLGC or LEXX more profitable?

Do analysts recommend FLGC or LEXX?

Does the media favor FLGC or LEXX?

Which has more volatility and risk, FLGC or LEXX?

Do insiders & institutionals have more ownership in FLGC or LEXX?

Which has higher valuation and earnings, FLGC or LEXX?

Summary

How does Flora Growth compare to Bullfrog AI?

Do institutionals and insiders have more ownership in BFRG or FLGC?

Do analysts rate BFRG or FLGC?

Does the media refer more to BFRG or FLGC?

Is BFRG or FLGC more profitable?

Which has stronger valuation and earnings, BFRG or FLGC?

Which has more volatility & risk, BFRG or FLGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools